{"id":26132,"date":"2024-07-16T09:37:55","date_gmt":"2024-07-16T07:37:55","guid":{"rendered":"https:\/\/idibell.cat\/?p=26132"},"modified":"2024-07-16T09:37:55","modified_gmt":"2024-07-16T07:37:55","slug":"un-estudi-de-lidibell-i-lico-demostra-els-avantatges-dadministrar-quimioterapia-abans-de-la-cirurgia-en-cancer-de-mama-estadi-ii-i-iii","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2024\/07\/un-estudi-de-lidibell-i-lico-demostra-els-avantatges-dadministrar-quimioterapia-abans-de-la-cirurgia-en-cancer-de-mama-estadi-ii-i-iii\/","title":{"rendered":"Un estudi de l\u2019IDIBELL i l\u2019ICO demostra els avantatges d\u2019administrar quimioter\u00e0pia abans de la cirurgia en c\u00e0ncer de mama estadi II i III"},"content":{"rendered":"

La quimioter\u00e0pia neoadjuvant, administrada abans de la cirurgia, ofereix m\u00faltiples avantatges per a les pacients amb c\u00e0ncer de mama. A m\u00e9s de facilitar la cirurgia de la mama i l\u2019axil\u00b7la, permet als metges observar com respon el tumor al tractament en temps real, oferint informaci\u00f3 valuosa per ajustar els tractaments posteriors segons la resposta observada.<\/p>\n

Ara, investigadors de l’IDIBELL i l\u2019Institut Catal\u00e0 d\u2019Oncologia, en col\u00b7laboraci\u00f3 amb professionals de l\u2019Hospital Universitari de Bellvitge, han publicat un estudi retrospectiu que ofereix una valoraci\u00f3 general de la seva efic\u00e0cia, aportant noves perspectives sobre els seus beneficis i resultats a llarg termini.<\/p>\n

L’estudi, realitzat en una cohort de 482 pacients amb c\u00e0ncer de mama en estadi II i III tractades entre el 2009 i el 2016, va analitzar l’efic\u00e0cia de la quimioter\u00e0pia basada en antraciclines i taxans, amb l’addici\u00f3 de ter\u00e0pies anti-HER2 en els casos positius per HER2. Els resultats, publicats recentment a la revista Cancers<\/a>, han sigut molt optimistes: un 25% de les pacients van assolir una resposta patol\u00f2gica completa, especialment les pacients HER2 positives (51%) i les triple negatives (31%), el que s\u2019ha tradu\u00eft en millora de la superviv\u00e8ncia a llarg termini.<\/p>\n

Alguns dels factors clau que van influir en la superviv\u00e8ncia de les pacients van ser el tipus de tumor, la resposta a la quimioter\u00e0pia, el tipus de cirurgia i la pres\u00e8ncia d’invasi\u00f3 vascular. Un dels descobriments m\u00e9s interessants va ser que les portadores del gen BRCA tenien una millor superviv\u00e8ncia, tot i que no va arribar a ser estad\u00edsticament significatiu, probablement pel menor n\u00famero de casos (9% del total).<\/p>\n

Per altra banda, l’estudi tamb\u00e9 va mostrar que les pacients en que es va poder oferir una cirurgia conservadora de la mama despr\u00e9s de la quimioter\u00e0pia tenien la meitat de risc de recurr\u00e8ncia a dist\u00e0ncia en comparaci\u00f3 amb aquelles que van requerir mastectomia, destacant la seguretat de la cirurgia conservadora despr\u00e9s de quimioter\u00e0pia neoadjuvant.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

La quimioter\u00e0pia neoadjuvant en c\u00e0ncer de mama facilita la cirurgia i ofereix valor pron\u00f2stic. La superviv\u00e8ncia a 10 anys \u00e9s del 84% i un 96% de les pacients que tenen una resposta completa a la quimioter\u00e0pia no arriben a tenir met\u00e0stasi.<\/p>\n","protected":false},"author":8,"featured_media":26133,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452],"tags":[],"class_list":["post-26132","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-de-mama","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure"],"publishpress_future_action":{"enabled":false,"date":"2025-01-02 11:50:47","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26132"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26132\/revisions"}],"predecessor-version":[{"id":26134,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26132\/revisions\/26134"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26133"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}